Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Trinity Biotech (TRIB) EBITDA Margin (2016 - 2024)

Historic EBITDA Margin for Trinity Biotech (TRIB) over the last 16 years, with Q4 2024 value amounting to 72.61%.

  • Trinity Biotech's EBITDA Margin fell 444600.0% to 72.61% in Q4 2024 from the same period last year, while for Dec 2024 it was 34.38%, marking a year-over-year increase of 132100.0%. This contributed to the annual value of 34.38% for FY2024, which is 132000.0% up from last year.
  • According to the latest figures from Q4 2024, Trinity Biotech's EBITDA Margin is 72.61%, which was down 444600.0% from 16.88% recorded in Q3 2024.
  • In the past 5 years, Trinity Biotech's EBITDA Margin ranged from a high of 28.38% in Q3 2020 and a low of 106.86% during Q2 2023
  • Moreover, its 5-year median value for EBITDA Margin was 14.44% (2022), whereas its average is 17.79%.
  • As far as peak fluctuations go, Trinity Biotech's EBITDA Margin crashed by -948600bps in 2023, and later surged by 812900bps in 2024.
  • Quarter analysis of 5 years shows Trinity Biotech's EBITDA Margin stood at 27.67% in 2020, then tumbled by -90bps to 2.88% in 2021, then tumbled by -1899bps to 51.87% in 2022, then soared by 46bps to 28.14% in 2023, then crashed by -158bps to 72.61% in 2024.
  • Its EBITDA Margin stands at 72.61% for Q4 2024, versus 16.88% for Q3 2024 and 25.58% for Q2 2024.